Dianthus Therapeutics与Leads Biolabs达成独家许可协议,推出DNTH212——首个且可能是首屈一指的1期准备阶段双功能Bdca2及Baff/April抑制剂,针对重度自身免疫疾病。
Dianthus Therapeutics与Leads Biolabs达成独家许可协议,推出DNTH212——首个且可能是首屈一指的1期准备阶段双功能Bdca2及Baff/April抑制剂,针对重度自身免疫疾病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.